Drug Trial Radar · NCT01702571
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,185
Actual
Start
Nov 27, 2012
Primary completion
Jul 31, 2020
Study completion Jul 31, 2020
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 8, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
Conditions
- Breast Cancer
Interventions
Trastuzumab EmtansineDrug
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events of Primary Interest (AEPIs)Time frame: Baseline up to approximately 7 years
Locations
300 sites in 43 countries. Site status is shown where the registry gives one.
CEMIC
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Hospital Privado De Comunidad; General Practice
Mar del Plata, Argentina
Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research
North Sydney, New South Wales, Australia
Calvary Mater Newcastle; Medical Oncology
Waratah, New South Wales, Australia
Westmead Hospital; Medical Oncology and Pallative Care
Westmead, New South Wales, Australia
Haematology & Oncology Clinics of Australia Research Centre
South Brisbane, Queensland, Australia
Ashford Cancer Center Research
Kurralta Park, South Australia, Australia
Peter MacCallum Cancer Centre; Medical Oncology
Melbourne, Victoria, Australia
Sunshine Hospital; Oncology Research
St Albans, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Salzburg, Austria
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
Vienna, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
Vienna, Austria
Institut Jules Bordet
Anderlecht, Belgium
UZ Brussel
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
GHdC Site Notre Dame
Charleroi, Belgium
UZ Antwerpen
Edegem, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
CHU Sart-Tilman
Liège, Belgium
Clinique Ste-Elisabeth
Namur, Belgium
Sint Augustinus Wilrijk, Apotheek
Wilrijk, Belgium
*X*Instituto Nacional do Cancer - INCA
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisas Oncologicas - CEPON
Florianópolis, Santa Catarina, Brazil
Hospital Sirio Libanes; Centro de Oncologia
São Paulo, São Paulo, Brazil
Hospital Sao Jose
São Paulo, São Paulo, Brazil
MHAT Serdika; Department of medical oncology
Sofia, Bulgaria
SHATO - Sofia
Sofia, Bulgaria
SHATOD - Sofia
Sofia, Bulgaria
District Oncology Dispensary Wit Stationary
Varna, Bulgaria
BC Cancer - Surrey
Surrey, British Columbia, Canada
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Dr. H. Bliss Murphy Cancer Centre; Oncology
St. John's, Newfoundland and Labrador, Canada
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
Barrie, Ontario, Canada
London Regional Cancer Centre
London, Ontario, Canada
Southlake Regional Health Center; Community Care Clinic / Oncology
Newmarket, Ontario, Canada
St. Michael'S Hospital
Toronto, Ontario, Canada
Showing 40 of 300 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.